sb 203580 has been researched along with ciprofibrate in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (ciprofibrate) | Trials (ciprofibrate) | Recent Studies (post-2010) (ciprofibrate) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 442 | 40 | 36 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Kim, YK; Kwon, CH; Yoon, CS | 1 |
2 other study(ies) available for sb 203580 and ciprofibrate
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Ciglitazone induces caspase-independent apoptosis via p38-dependent AIF nuclear translocation in renal epithelial cells.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Apoptosis Inducing Factor; Blotting, Western; Cell Line; Cell Nucleus; Cell Survival; Chromans; Clofibric Acid; Dose-Response Relationship, Drug; Epithelial Cells; Fibric Acids; Flow Cytometry; Fluorescent Antibody Technique; G1 Phase; Imidazoles; Kidney Tubules; Membrane Potential, Mitochondrial; Opossums; p38 Mitogen-Activated Protein Kinases; PPAR gamma; Pyridines; Thiazolidinediones; Troglitazone | 2008 |